LAVIPHARM S.A. (CR)

The current price of LAVI is 0.851 EUR — it has decreased by 0.35% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on ATHEX exchange LAVIPHARM S.A. (CR) stocks are traded under the ticker LAVI.

LAVI stock is 2.88% volatile and has beta coefficient of 1.28. Check out the list of the most volatile stocks — is LAVIPHARM S.A. (CR) there?

Yes, you can track LAVIPHARM S.A. (CR) financials in yearly and quarterly reports right on TradingView.

LAVI stock has risen by 0.47% compared to the previous week, the month change is a 3.73% fall, over the last year LAVIPHARM S.A. (CR) has showed a 118.77% increase.

LAVI net income for the last quarter is ‪−347.00 K‬ EUR, while the quarter before that showed ‪2.22 M‬ EUR of net income which accounts for −115.64% change. Track more LAVIPHARM S.A. (CR) financial stats to get the full picture.

No, LAVI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, LAVI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LAVIPHARM S.A. (CR) stock right from TradingView charts — choose your broker and connect to your account.

LAVI reached its all-time high on Jan 15, 2007 with the price of 6.198 EUR, and its all-time low was 0.050 EUR and was reached on Sep 19, 2016.
See other stocks reaching their highest and lowest prices.

As of Apr 30, 2024, the company has 307.00 employees. See our rating of the largest employees — is LAVIPHARM S.A. (CR) on this list?

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LAVIPHARM S.A. (CR) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LAVIPHARM S.A. (CR) stock shows the buy signal. See more of LAVIPHARM S.A. (CR) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LAVIPHARM S.A. (CR) EBITDA is ‪8.35 M‬ EUR, and current EBITDA margin is 16.39%. See more stats in LAVIPHARM S.A. (CR) financial statements.